Table 4

Multivariable Cox model fit: relative hazards of adverse events, with two different antiretroviral therapy encodings (n=1,096)
Factor RH 95% CI p-value
Lower Upper
calendar year (per more recent) 1.01 0.96 1.07 0.6462
gender M vs. F 0.52 0.38 0.71 <0.0001
age per one year older 1.04 1.02 1.05 <0.0001
nationality non-Italian vs. Italian 0.82 0.57 1.17 0.2724
nationality unknown vs. Italian 1.08 0.62 1.87 0.7941
risk homo/bisexual vs. heterosexual 2.03 1.40 2.94 0.0002
risk IDU vs heterosexual 1.16 0.75 1.79 0.5153
risk other/unknown vs. heterosexual 0.74 0.52 1.07 0.1090
years from first positive test 0.99 0.96 1.02 0.3804
CDC stage B vs. A 1.10 0.79 1.54 0.5716
CDC stage C vs. A 1.57 1.14 2.15 0.0051
HBsAg positive vs. negative 1.67 1.04 2.69 0.0356
HBsAg unknown vs. negative 1.11 0.54 2.28 0.7780
HCVAb positive vs. negative 1.02 0.69 1.52 0.9109
HCVAb unknown vs. negative 0.68 0.34 1.36 0.2766
CD4+ per cell/mm3 higher 1.00 1.00 1.00 0.8679
HIV-RNA per Log10 higher 0.85 0.68 1.07 0.1761
subtype 17 BF vs. B 1.49 0.81 2.75 0.1973
subtype 28 BF vs. B 0.96 0.56 1.65 0.8714
subtype 29 BF vs. B 0.90 0.38 2.15 0.8113
subtype C vs. B 1.87 0.83 4.18 0.1289
subtype F1 vs. B 1.89 0.94 3.83 0.0747
subtype other vs. B 1.46 0.75 2.86 0.2691
subtype unknown vs. B 0.95 0.70 1.29 0.7441
bilirubin high vs. normal 1.02 0.46 2.26 0.9576
bilirubin unknown vs. normal 0.67 0.42 1.06 0.0845
hemoglobin normal vs. low 0.97 0.66 1.40 0.8525
hemoglobin unknown vs. low 0.91 0.47 1.78 0.7903
gammaGT high vs. normal 0.93 0.62 1.39 0.7125
gammaGT unknown vs. normal 1.12 0.77 1.64 0.5507
glucose diabetes vs. normal 1.55 0.80 3.01 0.1959
glucose high vs. normal 1.73 0.92 3.26 0.0888
glucose unknown vs. normal 1.04 0.55 1.96 0.9142
GPT high vs. normal 1.20 0.87 1.66 0.2757
GPT unknown vs. normal 0.70 0.37 1.32 0.2691
HDL normal vs. low 1.04 0.60 1.81 0.8911
HDL unknown vs. low 0.97 0.35 2.67 0.9476
LDL high vs. normal 1.51 0.56 4.03 0.4137
LDL unknown vs. normal 1.62 0.58 4.51 0.3551
TGL high vs. normal 0.95 0.63 1.42 0.8048
TGL unknown vs. normal 1.65 1.11 2.44 0.0125
MDRD normal vs. low 1.41 0.58 3.41 0.4430
MDRD unknown vs. low 1.94 0.69 5.45 0.2098
anti-HCV therapy 0.73 0.22 2.41 0.6107
anti-TB therapy 0.93 0.63 1.37 0.7013
anti-PCP therapy 0.93 0.68 1.27 0.6533
other antibiotic therapy 0.99 0.71 1.37 0.9389
other concomitant drugs 0.76 0.56 1.03 0.0785
Atripla® vs. Truvada®+Sustiva® 0.99 0.12 8.44 0.9901
Reyataz® vs. Truvada®+Sustiva® 0.27 0.03 2.27 0.2270
Kaletra® vs. Truvada®+Sustiva® 1.26 0.53 2.96 0.6025
any other therapy vs. Truvada®+Sustiva® 1.11 0.39 3.20 0.8408
any other NRTI+NNRTI vs. Truvada®+Sustiva® 1.56 0.64 3.83 0.3267
any other NRTI+PI vs. Truvada®+Sustiva® 1.59 0.62 4.04 0.3339
any other NRTI+PI/r vs. Truvada®+Sustiva® 3.89 1.38 10.95 0.0101
Emtricitabine* (in the cART, yes vs. no) 1.19 0.46 3.07 0.7127
Lamivudine* (in the cART, yes vs. no) 1.21 0.70 2.09 0.5004
Abacavir* (in the cART, yes vs. no) 2.33 0.93 5.87 0.0719
Zidovudine* (in the cART, yes vs. no) 3.51 1.34 9.18 0.0107
Stavudine* (in the cART, yes vs. no) 2.84 1.06 7.60 0.0375
Zalcitabine* (in the cART, yes vs. no) 3.47 1.29 9.34 0.0136
Didanosine* (in the cART, yes vs. no) 2.27 1.29 3.98 0.0042
Tenofovir* (in the cART, yes vs. no) 2.00 0.65 6.20 0.2282
Nevirapine* (in the cART, yes vs. no) 1.42 0.67 2.98 0.3586
Efavirenz* (in the cART, yes vs. no) 2.40 1.14 5.03 0.0205
Atazanavir* (in the cART, yes vs. no) 0.15 0.02 1.34 0.0898
Fosamprenavir* (in the cART, yes vs. no) 2.77 0.76 10.09 0.123
Indinavir* (in the cART, yes vs. no) 1.76 1.04 3.00 0.0357
Lopinavir* (in the cART, yes vs. no) 0.55 0.23 1.33 0.1843
Nelfinavir* (in the cART, yes vs. no) 1.37 0.66 2.86 0.396
Ritonavit full dose* (in the cART, yes vs. no) 2.76 1.39 5.52 0.0039
Saquinavir* (in the cART, yes vs. no) 1.75 0.91 3.36 0.0922
Ritonavir boosting dose* (in the cART, yes vs. no) 1.19 0.41 3.44 0.7527

*Substituting anti-HIV therapy encoding (iv) to (ii) and fitting with the other covariates (single drugs’ RH are mutually adjusted). Note that both encoding (i) that compared 2NRTI+1NNRTI, 2NRTI+1PI, 2NRTI+1PI/r, others, and encoding (iii) that compared therapy combinations with a frequency of at least 10, did not show significantly different hazards (at p=0.05 level).

Prosperi et al.

Prosperi et al. BMC Infectious Diseases 2012 12:296   doi:10.1186/1471-2334-12-296

Open Data